Full-Time

Senior Manufacturing Associate

Alamar Biosciences

Alamar Biosciences

201-500 employees

Automates high-throughput proteomics for biomarker detection

Compensation Overview

$85k - $100k/yr

+ Bonus + Equity

Fremont, CA, USA

In Person

Authorized to work in the United States; E-Verify participation.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Biochemistry

Get referred to Alamar Biosciences

See people who can refer or advise you

Requirements
  • A B.S. or B.A. degree in Biology, Chemistry or equivalent with 6+ years of relevant experience in reagents manufacturing.
Responsibilities
  • Perform processing and conjugation of antibodies and lyophilization of critical components for downstream manufacturing.
  • Formulate standard to complex biochemical and chemical reagents in accordance with manufacturing records, Standard Operating Procedures, and Quality System regulations.
  • Assist in other manufacturing activities deemed high priority such as filling and packaging, label printing, and special builds, etc.
  • Perform batch records review and sign off to ensure completeness and compliance to Quality System standards.
  • Support production scheduling and assignment of job duties to team members.
  • Provide training, mentoring, and coaching to team members with similar or less experience
  • Address and investigate production issues and report any compliance related concerns to supervisor and/or management as soon as possible.
  • Ensure equipment and instruments are current with calibration and preventive maintenance, and general maintenance.
  • Participate in verification and validation to transfer new products/processes from R&D into Manufacturing, including executing on protocols, gathering data and/or report generation.
  • Initiate process improvement projects to improve productivity, quality, cost, or yield.
  • Draft, review, or revise manufacturing documents and procedures.
  • Perform change management as required to support product and process change and document change.
  • Participation in the selection and training of new employees.
  • Act as Lead when Specialist/Supervisor is unavailable.
  • Participate in internal and external safety and quality inspections.
  • Enforce a safe working environment and compliance with all safety laboratory practices.
Desired Qualifications
  • Experience in lyophilization highly preferred.
  • Experience in ISO 13485 and GMP environment a plus.
  • Previous experience with ERP System preferred

Alamar Biosciences provides access to a high-throughput proteomics platform built around NULISA™, a sensitive method for detecting and measuring proteins, and the ARGO™ system, a fully automated workflow for profiling hundreds to thousands of protein targets. It serves researchers and clinicians who need to detect low-abundance protein biomarkers with multiplexing capabilities, paying for use of the technology and platform rather than selling a standalone instrument. The core difference from competitors is its combination of ultra-sensitive protein detection across a wide range and an automated, scalable workflow that reduces the need for specialized expertise, enabling single-target or large-scale multiplex experiments. The company’s goal is to advance understanding of protein roles in health and disease, enabling early disease detection and the development of new diagnostics and treatments through repeatable, high-throughput proteomics.

Company Size

201-500

Company Stage

IPO

Headquarters

Hayward, California

Founded

2018

Get referred to Alamar Biosciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $29.4 million, up 82%, with 60% gross margin.
  • August 2026 guidance raised to $116 million-$120 million, driven by consumables and placements.
  • July 2026 Gates Ventures and AD Data Initiative partnership expands to 140,000 Alzheimer’s samples.

What critics are saying

  • Olink’s Delaware patent suit reopened April 2026; an injunction would cripple NULISA sales.
  • Rapid headcount growth to 286 employees lifted Q2 2026 operating expenses to $31.2 million.
  • Without FDA authorization for ARGO HT DX by 2027, clinical revenue stays research-only.

What makes Alamar Biosciences unique

  • NULISA detects attomolar blood proteins with automation, multiplexing, and broad dynamic range.
  • ARGO HT deployed across installed base now runs new Neuro 220 and Immune 340 panels.
  • Alamar pairs research tools with FDA-track ARGO HT DX, targeting clinical diagnostics in 2027.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

401(k) Retirement Plan

Performance Bonus

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-3%

2 year growth

-4%
Yahoo Finance
Aug 10th, 2026
Alamar Biosciences posts $29.4M Q2 revenue, beats loss estimates with proteomics focus

Alamar Biosciences reported a second-quarter loss of $13.2 million, or 22 cents per share, beating analyst expectations of a 36-cent loss. The Fremont, California-based proteomics company posted revenue of $29.4 million for the period. Proteomics involves the study and measurement of proteins in the body. Alamar forecasts full-year revenue between $116 million and $120 million. The results exceeded Wall Street projections based on estimates from three analysts surveyed by Zacks Investment Research.

MarketBeat
Aug 10th, 2026
Alamar Biosciences Q2 earnings call highlights.

Alamar Biosciences Q2 earnings call highlights. August 10, 2026 Key points. * Revenue surged 82% year over year to $29.4 million in Q2 2026, driven primarily by consumables revenue, which rose 147% to $15.5 million. Gross margin reached a record 60% as higher-margin consumables and manufacturing efficiencies improved the product mix. * Alamar ended the quarter with $256.3 million in cash, investments and restricted cash after raising $197.8 million in net IPO proceeds, although its operating loss widened to $13.5 million amid increased research, sales and public-company expenses. * Management forecast 2026 revenue of $116 million to $120 million and plans to add at least 100 instruments while expanding its neurology and immune panel offerings. Longer-term priorities include an FDA submission for the ARGO HT DX clinical instrument and additional diagnostic partnerships. * MarketBeat previews top five stocks to own in September. Alamar Biosciences NASDAQ: ALMR reported second-quarter 2026 revenue of $29.4 million, up 82% from $16.2 million a year earlier, as growth in consumables, instrument placements and service revenue supported the company's first earnings call since completing its April initial public offering. Chief Executive Officer Yuling Luo said the quarter reflected continued adoption of the company's precision proteomics platform, which combines ultra-high sensitivity, specificity, multiplexing, dynamic range and automation. The company's ARGO HT platform is used in research applications, with an initial focus on neurology and inflammation. "Q2 2026 was a strong quarter that reflects the momentum of our business," Luo said. Consumable revenue represented 53% of total revenue and grew 147% year over year, while the company achieved a 60% gross margin for the first time. Revenue growth driven by consumables. Chief Financial Officer Justin McAnear said consumables revenue totaled $15.5 million in the quarter, driven by demand for multiplex panel kits as the installed base expanded. Instrument revenue increased 35% to $7.8 million, while service and other revenue rose 49% to $6.2 million. Service revenue includes the company's Technology Access Program, or TAP, as well as maintenance contracts. McAnear said TAP is intended to support customer acquisition, custom assay development and product beta testing rather than operate as a long-term service business. The Q2 increase was primarily attributable to larger custom assay development projects. During the question-and-answer session, President Tod White said TAP activity was higher than management had expected in the second quarter and should continue into the third quarter, though not at the Q2 level. He characterized the service pipeline as a potential leading indicator of future instrument and consumable demand. Geographically, the Americas accounted for 69% of second-quarter revenue, followed by Europe, the Middle East and Africa at 22% and Asia-Pacific at 9%. Academic and research institutions generated 52% of revenue, biopharmaceutical customers contributed 42%, and distributors represented the remaining 6%. Luo said both academic and biopharmaceutical customer segments experienced strong growth during the quarter. White added that most year-to-date instrument placements have gone to new customers, although existing customers have also been adding instruments and, in some cases, expanding platform use to additional sites. Margins improve as product mix shifts. Gross profit increased to $17.7 million from $8.6 million a year earlier, and gross margin improved to 60% from 53%. McAnear attributed the expansion to manufacturing efficiencies as consumable production scaled and to a greater revenue contribution from consumables, which carry higher margins than instruments. Discover more EV Market Report Stock Average Calculator MarketBeat Research Tools White said gross margin could fluctuate in the mid-to-high 50% range in the near term, depending on the mix of instruments, consumables and services. However, he said management expects margins to trend higher over time as consumables become a larger share of revenue. Operating expenses rose to $31.2 million from $16.5 million in the prior-year quarter. Research and development expense increased 55% to $13.8 million, reflecting laboratory supply and personnel costs associated with expanding the company's panel menu. Selling, general and administrative expense rose 129% to $17.4 million, driven by personnel and higher legal and accounting expenses associated with becoming a public company. Alamar reported a $13.5 million operating loss, compared with a $7.9 million loss a year earlier. Net loss was $13.2 million, versus $7 million in the second quarter of 2025. The company recorded $3.3 million in stock-based compensation during the quarter. As of June 30, Alamar had $256.3 million in cash equivalents, short-term investments and restricted cash. McAnear said the April IPO generated $197.8 million in net proceeds. The company also refinanced its debt facility with SVB First Citizens Bank, establishing a revolving credit facility with $60 million available at closing and a further $40 million uncommitted accordion. New panels and large neurology studies. Alamar launched the NULISAseq Neuro 220 Panel in March and introduced a multiplex blood-based immunoassay for eMTBR-Tau in July. Luo said eMTBR-Tau is designed to measure tau tangle burden from blood samples and can be multiplexed with other neurodegeneration and neuroinflammation biomarkers. The company also launched the NULISAseq Immune 340 Panel, which measures approximately 340 immune-related proteins from a single blood sample, and introduced a dried blood spot extraction kit designed to make home-collected fingerstick samples compatible with its platform. Luo said Alamar added more than 40 publications and preprints during the quarter, bringing its cumulative total to 165. At the Alzheimer's Association International Conference, the company counted more than 140 posters and presentations featuring NULISA technology, a fourfold increase from the prior year. The company also expanded its partnership with the Alzheimer's Disease Data Initiative and Gates Ventures to add profiling of 86,000 plasma samples using the Neuro 220 Panel. The expanded agreement includes a national-scale initiative involving approximately 21,000 plasma samples from 10,000 Alzheimer's Disease Research Center participants. The combined dataset is expected to include more than 140,000 samples and be completed in 2027. 2026 outlook and clinical strategy. Alamar forecast full-year 2026 revenue of $116 million to $120 million, representing 59% annual growth at the midpoint. Management expects third-quarter revenue to increase modestly sequentially from the second quarter, which White described as low-single-digit sequential growth. For the full year, the company aims to add at least 100 instruments to its installed base and maintain annual per-instrument pull-through above $400,000. White said quarterly pull-through can fluctuate as new instruments are placed, and the company plans to report installed-base and average pull-through metrics annually. Looking toward 2027, Alamar plans to launch a multiplex panel targeting another disease area, submit its ARGO HT DX clinical instrument for FDA marketing authorization, and establish partnerships to support diagnostic test development. The company said it intends to invest IPO proceeds in commercial expansion, manufacturing capacity and research and development. About Alamar Biosciences (NASDAQ:ALMR). Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Alamar Biosciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alamar Biosciences wasn't on the list. While Alamar Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Associated Press
Jul 28th, 2026
Alamar Biosciences launches NULISAseq Immune 340 Panel for immune proteome profiling

Alamar Biosciences has launched the NULISAseq Immune 340 Panel, a multiplexed immune profiling solution for translational research and drug development. The panel measures approximately 340 immune-related proteins from a single sample, expanding on the company's previous Inflammation Panel 250. The new panel targets proteins circulating at very low concentrations, including cytokines, chemokines, and cell death pathway markers that are typically undetectable by conventional immunoassays. These biomarkers are relevant for studying cancer, cardiovascular and metabolic diseases, autoimmune conditions, and aging research. "The immune system holds some of the earliest and most informative signals of disease, yet much of that biology has been out of reach," said Dr Yuling Luo, founder and chief executive officer of Alamar. The panel aims to accelerate biomarker discovery and support development of new therapies and diagnostics.

Frontage Laboratories
Jul 21st, 2026
Frontage China becomes first Certified Service Provider in Asia Pacific & Greater China for Alamar Biosciences, strengthening global biomarker detection capabilities.

Frontage China becomes first Certified Service Provider in Asia Pacific & Greater China for Alamar Biosciences, strengthening global biomarker detection capabilities. EXTON, Pa., July 21, 2026 - Frontage China has officially been granted the Certified Service Provider (CSP) designation by Alamar Biosciences, becoming the first laboratory in the Asia-Pacific region and Greater China to receive this official accreditation. The certification integrates Frontage into Alamar Biosciences' global network of authorized service providers. Leveraging the ARGO(TM) HT System and the NULISA(TM) ultra-sensitive protein detection platform, Frontage will deliver high-quality, high-sensitivity protein biomarker testing services in strict accordance with Alamar's official standards, further enhancing its bioanalytical and translational medicine capabilities. The Alamar Biosciences Certified Service Provider (CSP) program is an official accreditation framework that recognizes laboratories possessing the technical expertise, quality systems, and operational capacity to perform NULISA(TM) platform testing to Alamar's specifications. Previously, the official CSP network was primarily concentrated in Europe and the Americas. Frontage China's attainment of CSP status not only fills a critical gap in the Asia-Pacific and Greater China regions but also provides regional biopharmaceutical innovators with more accessible, efficient, and internationally compliant testing solutions for drug development. With this achievement, both Frontage US and Frontage China now hold Alamar Biosciences CSP credentials. Operating under Frontage's "One World, One System" global unified quality framework, clients can access official-certified testing services that adhere to consistent standards across both China and the U.S., tailored to project requirements. This enables the generation of high-quality, comparable data to support global multi-center clinical trials and cross-regional drug development programs, while ensuring seamless project execution and data consistency across regions. Earning the Alamar Biosciences CSP designation marks a significant milestone in Frontage's ongoing commitment to expanding its global bioanalytical capabilities and underscores its international competitiveness in high-sensitivity protein biomarker detection. As a core pillar of Frontage's business, the bioanalytical platform has evolved over 25 years into a globally integrated network spanning the U.S., China, and Europe, offering comprehensive analytical solutions for small molecules, large molecules, biomarkers, and cell and gene therapy (CGT) products, all while meeting stringent international regulatory requirements. Powered by cutting-edge technology platforms, extensive project experience, and a globally harmonized quality management system, Frontage has become a trusted, long-term partner for numerous innovative drug developers and top 30 multinational pharmaceutical companies worldwide. Looking ahead, Frontage will continue to introduce advanced international technologies, broaden the frontiers of its bioanalytical capabilities, and elevate its global service offerings to provide clients with more comprehensive, efficient, and internationally aligned integrated R&D support. "Alamar Biosciences welcomes Frontage China to our global Certified Service Provider network," said a spokesperson from Alamar. "With Frontage's robust quality systems, expert technical teams, and extensive bioanalytical track record, this certification will significantly improve access to NULISA(TM) platform testing services for clients in the Asia-Pacific region, delivering more efficient and reliable technical support for global innovative drug development." About Frontage Frontage Laboratories, Inc. is a US-based global Contract Research, Development, and Manufacturing Organization (CRO/CDMO) offering fully integrated, science-driven solutions across the drug development journey. Founded in 2001 and headquartered in Pennsylvania, with 28 facilities across the U.S., Canada, Europe and China, Frontage provides seamless end-to-end capabilities - from drug discovery, API synthesis, DMPK, and safety & toxicology to formulation development and manufacturing, CMC analytical, clinical trials, bioanalytical and central lab services. With deep scientific expertise and strong operational execution, Frontage supports innovative, generic, and consumer health companies of all sizes in achieving IND, NDA, ANDA, BLA, and 505(b)(2) submissions - helping turn bold ideas into real-world therapies. SOURCE Frontage Laboratories, Inc.

Associated Press
Jul 13th, 2026
Alamar Biosciences launches national proteomics initiative with top universities to advance blood-based biomarkers for Alzheimer's

Alamar Biosciences has partnered with leading research universities to launch a national proteomics initiative for neurodegenerative disease biomarker research. The project, co-led by professors at Washington University, University of Wisconsin, and Indiana University, will analyse approximately 21,000 plasma samples from 10,000 Alzheimer's Disease Research Centre participants across the US. The initiative will use Alamar's NULISAseq Neuro 220 panel, which includes a newly added eMTBR-Tau assay for measuring tau tangle burden alongside neurodegeneration and neuroinflammation biomarkers. The platform offers attomolar sensitivity for detecting low-abundance proteins in blood. All generated data will be made freely available to the global research community, linked to longitudinal clinical, cognitive, neuroimaging, genetic and neuropathology data. The project aims to advance understanding of biological processes contributing to cognitive impairment and dementia.